Item 8.01 Other Events.

On January 6, 2022, Zai Lab Limited issued a press release announcing that the China National Medical Products Administration has accepted the new drug application (NDA) for margetuximab, an investigational, Fc-engineered monoclonal antibody that targets HER2. The margetuximab NDA is for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease, in combination with chemotherapy. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.       Description

99.1          Press Release issued by Zai Lab Limited on January 6, 2022.

104         The cover page of this Current Report on Form 8-K is formatted in
            Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses